Clinical Trial Update: Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia [Phase 2]

View source ↗

Summary

A phase 2 clinical trial evaluating the combination of acalabrutinib and obinutuzumab for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma is current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• CALQUENCE (ACALABRUTINIB)
• Gazyva (Obinutuzumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Status: RECRUITING